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Hintergrund:	 Der	 auf	 Makrophagen	 exprimierte	 “Scavenger“	 Rezeptor	 1	 (Msr1)	
vermittelt	 die	 Aufnahme	 modifizierter	 low-density	 Lipoproteine	 (mLDL)	 durch	
Makrophagen,	 ein	 entscheidender	 Schritt	 in	 der	 Entstehung	 von	 Atherosklerose.	
Sirt6,	 eine	 nukleäre	 NAD+-abhängige	 Deacetylase,	 aktiviert	 durch	 kalorische	
Restriktion,	hat	eine	protektive	Funktion	gegen	alters-assoziierte	Erkrankungen.	
Methoden	 und	 Resultate:	 Heterozygote	 Sirt6	 Deletion	 hatte	 keinen	 Einfluss	 auf	
Atherosklerose	 in	 ApoE-/-	Mäusen	 unter	 cholesterin-reicher	 Diät	 (high	 cholesterol	
diet,	 HCD)	 während	 12	 Wochen.	 	 Knochenmarks-spezifische	 Sirt6	 Deletion	
andererseits	erhöhte	die	Ausbildung	aortaler,	atherosklerotischer	Plaques	in	ApoE-/-	
Mäusen	 unter	 HCD.	 Aortenwurzel-Schnitte	 von	 Sirt6-defizienten,	 Knochenmarks-
transplantierten	 Mäusen	 wiesen	 erhöhte	 Lipid-Konzentrationen,	 Makrophagen-
Zahlen,	 VCAM-1	 Expression	 und	Msr1	 Levels	 auf	Makrophagen	 auf.	 Plasma	 Lipide	
derweil	 waren	 vergleichbar	 zwischen	 den	 Gruppen.	 In	 RAW	 264.7	 Makrophagen,	
erhöhte	 Sirt6	 Knockdown	 die	 Aufnahme	 Dil-markierten	 oxLDL’s	 ,	 während	 Sirt6	
Überexpression	 diese	 reduzierte;	 Silencing	 von	 Sirt6	 erhöhte	 die	 Expression	 von	
Msr1	 auf	mRNA-	 und	 Protein-Ebene,	 während	 die	 Expression	 anderer	 Lipoprotein	
Aufnahme-	 und	 Efflux-Rezeptoren	 auf	 Makrophagen	 unverändert	 blieb.	 Ein	
kombinierter	Knockdown	von	Sirt6	und	Msr1	 in	RAW	264.7	Zellen	verhinderte	eine	
gesteigerte	 oxLDL	 Aufnahme.	 Durchfluss-zytometrische	 Analyse	 von	Makrophagen	
aus	 aortalen	Plaques	 Sirt6-defizienter	Knochenmarks-transplantierter	Mäuse	 zeigte	
eine	 erhöhte	 Msr1	 Expression.	 Vergleichbare	 Resultate	 fanden	 sich	 bei	
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Knochenmarks-Zellen,	 während	 	 die	 Untersuchung	 peripherer	 Monozyten	 keine	
Unterschiede	in	der	Msr1-Expression	ergab.	
















Background:	 Macrophage	 Scavenger	 Receptor	 1	 (Msr1)	 mediates	 the	 uptake	 of	






(BM)-specific	 Sirt6	 deletion	 increased	 aortic	 plaque	 formation	 in	Apoe-/-	mice	 on	 a	
HCD.	 Aortic	 root	 sections	 from	 Sirt6-deficient	 BM-transplanted	 mice	 revealed	 an	
increase	in	lipid	content,	macrophage	numbers,	Vcam1	expression	and	macrophage	
Msr1	 levels.	 	 Plasma	 lipids	 were	 similar	 between	 the	 groups.	 In	 RAW	 264.7	















































































Atherosclerosis	 is	 the	 leading	 cause	 of	 cardiovascular	 disease	 and	 mortality	 in	
Western	countries	[1].	The	initiation	of	atherosclerosis	involves	the	accumulation	of	
oxidized	lipids	within	the	endothelium	of	the	arterial	walls,	which	progresses	to	form	
atherosclerotic	 lesions	 or	 plaques	 –	 the	 hallmark	 of	 the	 disease.	 Atherosclerotic	
plaques	 consist	 of	 asymmetrical	 plaque	 thickenings	 within	 the	 innermost	 sub-
endothelial	 layer	of	 the	artery,	 the	 intima	[2].	 In	 the	presence	of	excess	circulating	
LDL-cholesterol	 (LDL-c),	 increased	 LDL-c	 is	 taken	 up	 within	 the	 endothelial	 cells	
where	it	undergoes	modifications	like	oxidation	by	free	radicals	from	reactive	oxygen	
species,	thereby	being	transformed	into	pro-inflammatory	particles	namely	oxidized	
LDL	 (oxLDL)	 [3].	 These	 protein	 modifications	 enhance	 the	 binding	 of	 LDL	 to	
extracellular	 matrix	 components	 and	 result	 in	 the	 increased	 sub-endothelial	
retention	of	oxLDL.	oxLDL	 induces	expression	of	adhesion	molecules	 in	endothelial	
cells	 and	 stimulates	 vascular	 smooth	muscle	 cells	 (VSMCs)	 to	 release	 chemokines	
and	 chemo-attractants,	 leading	 to	 the	 recruitment	 of	 monocytes	 and	 T	 cells	 (as	
shown	 in	 Figure	 1).	 Upon	 tissue	 infiltration,	 monocytes	 become	 activated	 and	
differentiate	 to	macrophages.	 These	monocyte-derived	macrophages	 are	 recruited	
by	 endothelial	 chemokines	 and	 adhesion	 molecules	 expression,	 and	 they	
phagocytose	 the	 native	 and	 modified	 LDL	 (mLDL)	 through	 Fc-	 and	 scavenger	
receptors	to	become	foam	cells	[4].	
These	atherosclerotic	lesions	expand	over	time	and	result	in	the	narrowing	of	
the	 arterial	 lumen.	 If	 these	 events	 occur	 in	 coronary	 arteries	 of	 patients,	 relevant	
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narrowing	 may	 lead	 to	 angina	 pectoris,	 but	 this	 is	 rarely	 fatal	 in	 the	 absence	 of	
scarring	of	 the	myocardium	 [5].	 The	 susceptibility	of	 a	 coronary	plaque	 to	 rupture	
and	 form	a	blood	 clot	 (thrombus)	with	 total	 artery	 occlusion	 is	 the	most	 frequent	
cause	of	acute	coronary	syndromes	(ACS)	[6].	Histological	analyses	of	atherosclerotic	
thrombi	have	shown	that	more	than	40%	of	the	volume	of	most	disrupted	plaques	
contain	 a	 necrotic	 lipid	 core,	 consisting	 of	 lipids,	 cholesterol	 crystals	 and	 necrotic	
debris	surrounded	by	a	thin	fibrous	cap	[7].	
		
Figure	 1:	 Step-wise	 scheme	 of	 atherogenesis	 and	 plaque	 rupture:	 The	 first	 event	 in	 the	
plaque	 formation	 is	 endothelial	 dysfunction	 characterised	 by	 activation	 of	 adhesion	
molecules	 like	 ICAM-1	 and	VCAM-1	 (Step	1).	 This	 facilitates	 the	 attachment	 and	 rolling	of	
circulating	monocytes	and	their	entry	into	the	subendothelial	space	(Step	2).	The	monocytes	
differentiate	to	form	macrophages,	which	engulf	and	accumulate	the	modified	lipids	to	form	
foam	 cells	 (Step	 3).	 The	 vascular	 smooth	 muscle	 cells	 (VSMC)	 proliferate	 and	 synthesize	
collagen	that	forms	the	fibrous	cap	enclosing	the	lipid	core	(Step	4).	Apoptosis	of	the	VSMC	














responses.	 This	 dysregulation	 of	 the	 local	 lipid	 metabolism	 alters	 macrophage	
phenotypes	and	ensues	an	inflammatory	immune	response	[9].		
Scavenger	 receptors	 are	 one	 of	 the	main	 PRRs	 expressed	 by	macrophages	
and	 play	 an	 important	 role	 in	 macrophage	 function	 and	 metabolism.	 They	 are	
surface	receptors	and	have	a	large	spectrum	of	endogenous	and	exogenous	ligands	





macrophage	 scavenger	 receptor	 1	 (Msr1;	 also	 known	 as	 SR-A1),	 macrophage	
receptor	 with	 collagenous	 structure	 (MARCO;	 also	 known	 as	 SR-A2),	 CD36	 (also	
known	as	platelet	glycoprotein	4),	scavenger	receptor	B1	(SR-B1),	lectin-like	oxidized	
LDL	 receptor	 1	 (LOX1),	 and	 scavenger	 receptor	 expressed	 by	 endothelial	 cells	 1	
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(SREC1)	and	can	take	up	modified	 forms	of	LDL	and	 lead	to	the	 formation	of	 foam	
cells	[10].		
Table	1.	Scavenger	Receptor	Family,	Cell	Types,	Functions,	and	Ligands		
Class/Name	 Cell	Type		 Function	 Major	Ligands		



























SREC	1	 Endothelial	cells		 Unknown		 AcLDL,	oxLDL		
LOX-1		 Endothelial	cells		 Unknown		 OxLDL		
	
Of	all	scavenger	receptors,	the	role	of	Msr1	is	the	most	widely	studied	in	the	
pathogenesis	 of	 atherosclerosis.	Msr1	 is	 a	 trimeric	 scavenger	 receptor.	 In	 humans	
and	mice	Msr1	 plays	 a	 critical	 role	 in	 oxLDL	 uptake	 and	 foam	 cell	 formation.	 For	
example,	overexpression	of	human	Msr1	gene	 in	mice	 is	associated	with	 increased	
foam	cell	formation	and	cholesterol	ester	accumulation	upon	incubation	with	oxLDL	
[11].	Msr1	is	also	highly	expressed	in	atherosclerotic	lesions	[12].	These	early	studies	





Since	 their	 description	 in	 1979	by	Goldstein	 et	 al.,	 scavenger	 receptors	 have	been	
defined	 by	 their	 ability	 to	 ‘scavenge’	 mLDL	 from	 their	 environment	 for	
internalization	 and	 subsequent	 degradation	 [13].	 The	 excess	 mLDL	 internalization	
and	retention	produces	massive	oxidation	and	deposition	of	intracellular	cholesterol.	
The	main	 ligands	 of	Msr1	 are	 known	 to	 be	 acetyl	 LDL	 (acLDL)	 in	 vitro	 and	 oxLDL.	
Msr1	can	bind	and	uptake	both	oxLDL	and	acLDL,	leading	to	an	increase	in	foam	cell	




the	disruption	of	exon	4	of	 the	Msr1	gene	 that	 is	critical	 for	 the	generation	of	 the	
trimeric	 functional	 receptor	 [14].	 Isolation	 and	 subsequent	 oxLDL	 treatment	 of	
resident	peritoneal	macrophages	from	Msr1-deficient	mice	show	an	80%	reduction	
in	 acLDL	 clearance	 and	 a	 30%	 reduction	 in	 oxLDL	 clearance	 [15].	 To	 study	 the	
relevance	of	Msr1	 in	 atherosclerosis,	Msr1	 KO	mice	were	 crossbred	with	 different	
mouse	 strains	 susceptible	 to	 atherosclerosis.	 On	 an	 Apoe-deficient	 background,	
Msr1-deficiency	 induced	 conflicting	 results:	 The	 first	 report	 described	 a	moderate	
increase	 in	 plasma	 cholesterol	 levels	 coinciding	 with	 a	 40%	 increase	 in	 lesion	
areas[16];	in	contrast,	other	studies	found	smaller	atherosclerotic	lesions	[17].	On	a	
LDL	 receptor	 (LDLR)-deficient	 background,	 the	 absence	 of	 Msr1	 results	 in	 a	 20%	





Msr1	 is	 important	 for	 the	 rapid	 removal	of	 apoptotic	 cells	 by	macrophages	
[19].	 In	addition	to	having	a	role	 in	 lipid	uptake	and	apoptotic	cell	clearance,	Msr1	
also	plays	a	critical	role	in	the	process	of	cell	adhesion	(Figure	2).	In	1993,	Fraser	et	al	
first	 elucidated	 this	 function	 of	 Msr1	 by	 developing	 a	 monoclonal	 antibody	 (2F8)	
directed	against	murine	Msr1	receptor	and	showed	that	2F8	 inhibited	the	calcium-
independent	adhesion	of	RAW	264	macrophages	to	tissue	culture	plastic	plates	[20].	
This	 was	 the	 first	 evidence	 that	 demonstrated	 that	 Msr1	 could	 mediate	 cellular	
adhesion.	 Subsequent	 studies	 showed	 that	 2F8	 could	 also	 block	 the	 adherence	 of	
macrophages	 in	 tissues.	 Peritoneal	macrophages	 from	Msr1	KO	mice	were	able	 to	
adhere	 to	 plastic	 dishes	 but	 the	 process	 was	 slower	 compared	 to	 wild-type	
macrophages,	 confirming	Msr1	 is	 essential	 for	macrophage	 adhesion	 in	 vitro	 [14].	
This	 effect	 on	 adhesion	 demonstrated	 a	 functional	 relevance	 of	 Msr1	 in	 the	
recruitment	and	retention	of	mononuclear	phagocytes	to	tissues,	such	as	endothelial	
cells	and	atherosclerotic	lesions	[17].	







3. Msr1	 mediates	 the	 adherence	 and	 interaction	 of	 the	 monocyte-derived	
macrophages	with	 other	 cells	 in	 the	 plaque	 such	 as	 endothelial	 cells,	 smooth	
muscle	cells,	and/or	other	macrophages.		
Figure	 2.	 Events	 regulated	 by	
Msr1	during	atherogenesis:	Msr1	
upregulated	 on	 circulating	
monocytes	 are	 involved	 in	
adhesion	of	monocytes	 to	 activa-
ted	 endothelium	 and	 their	 trans-
migration	 into	 the	 lesion.	Msr1	 is	
important	 for	 the	 release	 of	 pro-
inflammatory	 cytokines	 and	
mediates	 the	 uptake	 of	 modified	





Monocytes	 originate	 from	 bone	 marrow-derived	 progenitor	 cells.	 Cellular	
cholesterol	 content	 is	 known	 to	 influence	 early	 stages	 of	 monocyte	 development	
and	 subsequent	 atherogenesis	 [21].	 The	 absence	 of	 cholesterol	 efflux	 transporter-
ABCA1	 in	mouse	 progenitor	 cells	 increases	 the	 circulating	monocytes	 and	 ensuing	
atherosclerosis	[22].		
Peripheral	 blood	monocytes	 are	 not	 a	 homogeneous	 population	 (Table	 2).	
Monocyte	 heterogeneity	 was	 first	 reported	 with	 the	 identification	 of	 a	 minor	





the	 expression	 of	 the	 surface	 markers	 CD14	 and	 CD16	 [24].	 Based	 on	 this	
nomenclature,	 the	 major	 population	 of	 human	 monocytes	 (90%)	 expresses	 high	
CD14	but	no	CD16	expression	 (CD14++CD16–	 or	CD14+CD16–)	 are	 termed	classical	





The	 different	 subsets	 may	 have	 different	 roles	 during	 metabolic	 homeostasis,	
immune	 defense/inflammation,	 and	 tissue	 repair,	 depending	 on	 their	 capacity	 to	
become	 activated	 and/or	 secrete	 inflammatory	 cytokines	 in	 response	 to	 different	
stimuli,	antigen	processing	and	presentation.		In	general	terms,	both	human	classical	
and	 intermediate	 monocytes	 have	 inflammatory	 properties	 (also	 termed	
“inflammatory”	 monocytes)	 [25],	 while	 non-classical	 monocytes	 display	 patrolling	
properties	(also	termed	“alternative”	or	“patrolling”	monocytes)	[25].		Similar	to	the	
nomenclature	of	human	monocyte	subpopulations,	murine	monocytes	are	also	sub-
divided	 into	 Ly6Clow	 and	 Ly6Chi	 monocytes,	 where	 murine	 Ly6Chi	 are	 the	
inflammatory	 subtype	and	 Ly6Clow	 are	 the	 alternative/anti-inflammatory	monocyte	
subtype	[25].		





increase	 in	 the	 inflammatory	 Ly6Chi	 subset.	 This	 subpopulation	 constitutes	 the	
majority	of	cells	recruited	to	growing	atherosclerotic	plaques	and	which	is	thought	to	














Macrophages	 derived	 from	 monocyte	 precursors	 undergo	 specific	
differentiation	 depending	 on	 the	 local	 tissue	 environment.	 The	 activation	 and	
differentiation	to	different	macrophage	phenotypes	depends	on	the	environmental	
cues	 within	 tissues	 such	 as	 damaged	 cells,	 cytokines	 or	 lymphocytes.	 The	 M1	
macrophage	 phenotype	 is	 characterized	 by	 the	 production	 of	 high	 levels	 of	 pro-
inflammatory	cytokines	 in	an	effort	to	mediate	resistance	to	pathogens.	They	have	
strong	 microbicidal	 properties,	 produce	 high	 amounts	 of	 reactive	 nitrogen	 and	
oxygen	 intermediates,	 and	 promote	 Th1	 responses.	 Thus,	 M1	 macrophages	 are	
classically	activated	and	implicated	in	initiating	and	sustaining	inflammation	[29].	In	
contrast,	 M2	 macrophages	 are	 characterized	 by	 their	 involvement	 in	 parasite	
control,	 tissue	 remodeling,	 immune	 regulation,	 tumor	 promotion	 and	 efficient	
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phagocytic	 activity	 [30].	 They	 decrease	 inflammation	 and	 encourage	 tissue	 repair	
[31].		
The	polarization	 states	 between	M1	and	M2	 are	 to	 some	extent	 reversible	
and	 dependent	 on	 the	 local	 milieu	 in	 an	 atherosclerotic	 vessel.	 Within	 the	
atherosclerotic	 vessel	 wall,	 there	 is	 a	 mixed	 population	 of	 both	 M1	 and	 M2	





















animals	 [37].	 However,	 later	 studies	 demonstrated	 that	 if	 the	 metabolic	 rate	 is	
normalized	 to	 the	 lean	 body	 mass	 of	 the	 animals,	 there	 is	 an	 increase	 in	 caloric	
restricted	animals	[38].		This	was	an	important	finding	because	it	challenged	the	idea	
that	 the	 total	metabolic	 activity	 over	 the	 lifetime	 of	 the	 animal	was	 fixed.	 Caloric	
restricted	 animals	 enjoyed	more	 total	metabolic	 activity	 adjusted	 for	 body	weight	
over	their	lifetimes	than	did	the	ad	libitum-fed	controls.		
Genetic	 studies	 in	 model	 organisms	 like	 Caenorhabditis	 elegans,	 and	
Saccharomyces	 cerevisiae	 suggested	 that	 caloric	 restriction	 might	 be	 a	 tightly	
regulated	 process,	 with	 the	 gene	 Sir2,	 playing	 an	 important	 role.	 The	 Sir2	 gene	
transcript	 is	 a	 NAD+-dependent	 histone	 deacetylase	 [39]	 with	 NAD+	 acting	 as	
cofactor	 for	enzyme	activity	 [40,	41]	 (Figure	3).	 	Several	 studies	confirmed	the	 link	
between	caloric	restriction	and	Sir2	gene:	One	study	showed	caloric	restriction	does	
not	 extend	 life	 span	of	 yeast	 anymore	when	Sir2	was	deleted	 [42].	 Another	 study	
demonstrated	increased	Sir2	activity	in	vivo	upon	caloric	restriction	[43].	And	finally,	
the	 Sir2	 enzyme	 activator,	 resveratrol,	 was	 shown	 to	 extend	 yeast	 replicative	 life	
span	 [44].	 Overall,	 the	 activity	 of	 Sir2	 suggested	 that	 this	 protein	 senses	 the	
metabolic	state	of	cells	and	sets	the	lifespan	accordingly	[45].		
While	 being	 a	 substrate	 for	 Sir2	 activity,	 NAD+(H)	 and	 NADP+(H)	 are	 also	
essential	 coenzymes	 participating	 in	 many	 cellular	 redox	 reactions	 in	 all	 living	
system.	Thus,	reduced	NAD+	metabolism	is	 linked	to	many	diseases	such	as	cancer,	
metabolic	and	neurodegenerative	disorders	 [46].	 	Although	redox	 reactions	do	not	
alter	 the	 total	 cellular	 NAD+	 content,	 cellular	 processes	 such	 as	 Sir2-mediated	
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protein	 deacetylation	 consume	 NAD+.	 Hence	 it	 is	 critical	 to	 maintain	 a	 constant	
renewal	of	cellular	NAD+	 to	maintain	cellular	metabolism	 [46].	NAD+	 is	 synthesized	
from	a	number	of	precursor	molecules.	The	amino	acid	tryptophan	is	utilised	for	the	
de	 novo	 biosynthesis	 of	 NAD+.	 NAD+	 metabolites	 such	 as	 nicotinamide	 (NAM),	
nicotinic	 acid	 (NA)	 and	 nicotinamide	 riboside	 (NR)	 can	 also	 be	 salvaged	 and	 re-
assimilated	into	NAD+	(as	shown	in	figure	3).		
NAD+	 levels	 directly	 affect	 Sir2	 activity,	while	 on	 the	other	 hand	NADH	has	
been	shown	to	be	a	competitive	 inhibitor	of	Sir2.	 Lowering	NADH	 levels	causes	an	
increase	in	Sir2	activity	[42].	However,	NADH	is	a	weak	inhibitor	of	Sir2,	and	 in	vivo	
NADH	levels	are	too	low	to	result	in	the	inhibition	of	Sir2	activity	[47].	It	is	thus	likely	
that	 the	 intracellular	 compartmentalization	 of	 NAD+	 and	 NADH	 or	 local	 protein	
interactions	result	in	locally	high	NAD+/NADH	ratios,	which	activate	Sir2	in	vivo.	The	
dependence	 of	 Sir2	 activity	 on	 the	 intrinsic	 cellular	 levels	 of	NAD+	 and	 its	 high	 Km	




breakdown	 to	 nicotinamide	 and	 ADP-
ribose	with	 the	 removal	 of	 acetyl	 groups	
from	 histone	 and	 other	 proteins.	 The	
acetyl	 moiety	 is	 transferred	 to	 ADP-
ribose,	 creating	 acetyl-ADP	 ribose.	 This	
Sir2	 enzymatic	 activity	 links	 energy	






Elegans	 by	 the	 identification	of	 the	Sir2	gene	and	 its	 contribution	 to	 longevity	has	
been	extended	to	mammalian	systems	in	recent	years.		
The	 protective	 effects	 of	 Sir2	 on	 age-related	 diseases	 are	 conserved	 in	
mammals.	 In	mammals,	the	Sir2	orthologues	are	named	sirtuins.	The	sirtuin	family	
comprises	 of	 7	 genes,	 Sirt1	 to	 Sirt7	 which	 exert	 different	 protective	 effects	 (as	













Figure	 4:	 Sirtuins	 affect	 multiple	 diseases.	 Sirtuins	 are	 activated	 by	 elevated	 NAD+
	
levels	
induced	 during	 states	 of	 increased	 energy	 demand	 such	 as	 fasting,	 calorie	 restriction	 and	
exercise.	Sirtuins	deacetylate	(or	ADP-ribosylate)	numerous	transcription	factors,	cofactors,	





deacetylase,	 lysine	 deacylase	 and	 an	 ADP-ribosylase.	 Deficiency	 of	 Sirt6	 causes	 a	
strong	phenotype:	 Constitutive	 Sirt6	 deletion	 at	 the	whole	organism	 level	 confers	
accelerated	aging	with	a	progeria-like	phenotype	[52].	These	mice	die	prematurely	at	
about	 3-4	weeks	 of	 age	 and	 are	much	 smaller	 compared	 to	 their	 littermates	 [52].	
When	born,	these	mice	are	normal	for	about	2	weeks	but	they	then	exhibit	severe	
metabolic	defects.	After	2	weeks,	there	is	a	decline	in	serum	glucose	levels	causing	a	
state	 of	 hypoglycemia	 and	 low	 plasma	 Igf1	 levels	 –	 which	 is	 critical	 for	 bone	
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development.	 This	 results	 in	 brittle	 and	 thin	 bones	 and	 curved	 spine	 (termed	
lordokyphosis).	These	metabolic	defects	along	with	the	premature	aging	phenotype	
with	early	death	at	3	weeks	of	 age	make	Sirt6	extremely	 interesting	 candidate	 for	
age-related	 metabolic	 disorders	 such	 as	 cardiovascular	 disease	 and	 diabetes	
mellitus.	
At	 the	cellular	 level,	 the	 absence	of	 Sirt6	 results	 in	 genomic	 instability	 and	
increased	 susceptibility	 to	 damage	 induced	 by	 ionizing	 radiation	 (IR),	
methylmethanesulfonate	 (MMS),	 and	 hydrogen	 peroxide	 (H2O2)	 [53].	 Loss	 of	 Sirt6	
leads	 to	 the	 formation	of	dysfunctional	 telomeres,	 accumulation	of	 telomeric	DNA	
damage	 foci,	 and	 genomic	 instability	 with	 chromosomal	 end-to-end	 fusions	 that	
drive	the	cell	into	premature	senescence	[54].	Sirt6	also	plays	a	role	in	base	excision	
repair	 (BER)	and	double-strand	break	 (DSB)	 repair	 [55,	56].	Furthermore,	Sirt6	also	
ADP-ribosylates	 PARP1	 and	 stimulate	 its	 poly-ADP-ribosylation	 activity	 [57].	 Since	
PARP1	is	also	involved	in	both	BER	and	DSB	repair,	the	activation	of	PARP1	by	Sirt6	
may	also	explain	the	BER	defects	observed	in	Sirt6-deficient	cells.	The	defective	BER,	
DSB	 repair	 and	 telomere-dependent	 genomic	 instability	 that	might	 in	 part	 explain	
premature	aging	and	cellular	senescence	seen	in	Sirt6	knockout	mice.	








accessibility	 of	 transcription	 factors	 such	 as	 nuclear	 factor	 κB	 (NF-κB),	 c-JUN,	 Foxo3,	MYC,	
and	hypoxia	inducible	factor	1	α	(HIF1α)	to	their	respective	target	promoters,	thus	inhibiting	
target	gene	expression.	Sirt6	can	also	directly	regulate	protein	activity	through	deacetylation	







Sirt6	 is	 a	 key	 regulator	 of	glucose	metabolism	 (Figure	 5).	 As	 previously	 described,	
Sirt6	 knockout	 mice	 display	 hypoglycemic	 effects,	 which	 ultimately	 leads	 to	 their	
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death	 [52].	 	 A	 study	 investigating	whether	 Sir6	 is	 directly	 or	 indirectly	 involved	 in	
glucose	metabolism	demonstrated	that	Sirt6-deficient	embryonic	stem	cells	have	an	
upregulation	 of	 glycolytic	 genes	 such	 as	 Ldh,	 triose	 phosphate	 isomerase	 (Tpi),	
aldolase,	and	the	rate-	limiting	glycolytic	enzyme	phosphofructokinase-1	(Pfk-1)	[59].	
There	was	also	an	increase	in	pyruvate	dehydrogenase	kinase	genes	Pdk1	and	Pdk4.	
These	 enzymes	 phosphorylate	 and	 inhibit	 PDH,	 the	 rate-limiting	 enzyme	 that	
regulates	 entrance	 of	 pyruvate	 into	 the	 tricarboxylic	 acid	 (TCA)	 cycle	 [59].	 Sirt6	
modulates	glucose	homeostasis	specifically	through	a	Hif1α	-dependent	mechanism.	
Sirt6	 acts	 as	 a	 co-repressor	 of	 Hif1α.	 In	 the	 absence	 of	 Sirt6,	 the	Hif1-α	regulated	
glycolytic	gene	expression	increases.	Treatment	of	Sirt6-deficient	mice	with	a	HIF1α	
inhibitor	 rescued	 the	 hypoglycemic	 phenotype	 [60].	 Additionally,	 in	 Sirt6-deficient	
cells	there	is	an	increase	in	the	glucose	transporter	Glut1	and	a	pronounced	increase	
in	 the	 uptake	 of	 glucose	 by	muscles	 and	 the	 brown	 adipose	 tissue	 (BAT),	 both	 of	
which	might	also	partially	explain	the	hypoglycemic	effect	[59].		
Sirt6	 modulates	 lipid	 metabolism	 by	 influencing	 lipid	 clearance	 pathways	
(Figure	 5).	Hepatocyte-specific	 deletion	of	 Sirt6	 in	mice	 causes	 an	 increase	 in	 liver	
steatosis	 in	90%	of	 the	mice	 from	7.5–13	months	of	age.	These	mice	also	have	an	
increase	in	hepatic	triglyceride	levels	due	to	an	increase	in	triglyceride	synthesis	[61].	
Livers	 of	mice	with	 hepatocyte-specific	 Sirt6	 deletion	 show	 a	 higher	 expression	 of	
fatty	 acid	 translocase	 (Fat)	 with	 increased	 uptake	 of	 long	 chain	 fatty	 acids	 from	
blood	[61].		





secretion,	 and	 reduced	 expression	 of	 selected	 PPARγ-regulated	 genes	 involved	 in	
lipid	metabolism,	 lipid	 transport,	 and	 adipogenesis	 [62].	 Sirt6	 overexpressing	mice	
had	 lower	 levels	 of	 LDL-c,	 -one	 of	 the	main	 protagonists	 in	 cardiovascular	 disease	
(60).	 One	 of	 the	 mechanisms	 by	 which	 Sirt6	 lowers	 LDL-c	 is	 by	 regulating	 the	
expression	of	proprotein	convertase	subtilisin/kexin	type	9	(Pcsk9).	Secreted	Pcsk9	is	
known	to	 function	as	a	chaperone	and	 targets	 the	LDLR	 for	 lysosomal	degradation	
within	 hepatocytes	 [63].	 FoxO3	 recruits	 Sirt6	 to	 the	 promoter	 of	 the	 Pcsk9	 gene	
where	 it	deacetylates	histone	H3K9	and	H3K56,	 to	suppress	Pcsk9	gene	expression	
[64].	 By	 lowering	 Pcsk9,	 Sirt6	 improves	 LDLR	 recycling	 and	 increases	 clearance	 of	
LDL-c	[64].		
Sirt6	 also	 modulates	 lipid	 metabolism	 by	 regulating	 the	 sterol-sensing	
transcription	 actor	 sterol-regulatory	 element	 binding	 protein	 (Srebp)	 (described	 in	
Figure	5).	Srebp2,	an	isoform	of	Srebp,	is	a	key	regulator	of	cholesterol	biosynthesis.	
More	 than	one	mechanism	had	been	uncovered	by	means	of	which	 Sirt6	 controls	
Srebp2	 function.	 FoxO3	 recruits	 Sirt6	 to	 the	 Srebp2	 gene	 promoter	 where	 it	
deacetylates	 H3K9	 and	 H3K56	 at	 Srebp	 promoter	 and	 downregulates	 the	
transcription	of	its	target	genes	[65,	66].	Alternatively,	Sirt6	also	inhibits	the	cleavage	
of	 Srebp1/Srebp2	 into	 their	 active	 forms	 by	 decreasing	 the	 transcription	 of	 the	
Srebp1/Srebp2	protease	complexes	(SCAP,	S1P,	and	S2P)	[66].	The	third	mechanism	
of	modulation	Srebp2	 function	 is	by	 the	regulation	of	AMP/ATP	ratio	by	Sirt6.	This	




Sirt6	 can	 also	 hydrolytically	 remove	 long-chain	 fatty-acyl	 groups,	 including	





various	metabolic	pathways	 such	as	 fatty	 acid	 synthesis,	 beta	oxidation,	 glycolysis,	





that	 interacts	 with	 many	 metabolic	 and	 aging	 pathways.	 Numerous	 studies	 link	
sirtuins	 to	NF-κB	mediated	 signaling	 [68-70].	 	 Sirt1	has	been	 shown	 to	deacetylate	
NF-κB	and	downregulates	 its	 activity	 [68,	69].	Recently,	 studies	by	Kawahara	et	al.	
demonstrated	that	Sirt6	interacts	with	RelA	of	the	NF-κB	subfamily	and	is	recruited	
to	the	promoters	of	RelA	target	genes	[70].	This	in	turn	decreases	the	expression	of	
NF-κB	 target	 genes	 through	 deacetylation	 of	 H3K9	 at	 target	 gene	 promoters	 [70].	
Along	these	 lines,	heterozygous	deletion	of	RelA	restores	 the	reduced	 lifespan	and	
aging-	related	phenotypes	observed	in	Sirt6	KO	mice	[70].		
Sirt6	 homozygous	 KO	 mice	 on	 a	 mixed	 genetic	 background	 of	 129/Black	




Mcp1,	 indicating	 that	 inflammatory	 responses	 of	 Sirt6	 loss-of-function	 in	
macrophages	activates	c-Jun	signaling	[71].		
Above	 examples	 highlight	 the	 anti-inflammatory	 aspects	 of	 Sirt6-mediated	
responses.	 However,	 Sirt6	 can	 also	 exert	 an	 inflammatory	 response	 under	 certain	
conditions.	For	example,	Sirt6	can	catalyze	the	hydrolysis	of	myristoylated	lysine	19	
and	 20	 of	 tumor	 necrosis	 factor	 α	 (TNF-α),	 which	 enables	 the	 secretion	 of	 TNF-α	
from	 the	 mouse	 embryonic	 fibroblast	 (MEF)	 cells	 [67].	 TNF-α	 is	 a	 key	
proinflammatory	 cytokine	 that	 is	 known	 to	 play	 a	 major	 part	 in	 numerous	
inflammatory	 diseases.	 In	 vivo,	TNF-α	 has	 lower	 lysine	 fatty	 acylation	 and	 is	more	




Sirt6	 is	 known	 to	 play	 a	 role	 in	 cardiovascular	 disease.	 Sirt6	 deficiency	 causes	 an	
increase	in	cardiac	hypertrophy	and	degenerative	changes	to	the	heart.	In	line	with	
this	 it	 has	been	 shown	 that	 compared	 to	healthy	hearts,	 failing	hearts	 have	 lower	
Sirt6	expression	 levels	 [72].	 Furthermore,	hearts	 from	Sirt6-deficient	mice	have	an	
increase	in	expression	of	cardiac	fetal	genes,	an	increase	size	of	cardiomyocytes	and	
an	 increase	 in	 interstitial	 fibrosis.	 While	 on	 the	 other	 hand,	 Sirt6	 overexpression	
blocks	 these	 cardiac	hypertrophic	 response.	Mechanistically,	 Sirt6	 interacts	with	 c-
JUN,	which	 results	 in	 the	blocking	of	 IGF	signaling	by	 the	deacetylation	of	H3K9	at	
	
	 30	
IGF	downstream	 targets.	 Inhibition	of	 c-JUN	or	 IGF	 signaling	blocks	hypertrophy	 in	
Sirt6-deficient	hearts	[72].	
Recent	 studies	 also	 show	 that	 Sirt6	 may	 be	 protective	 in	 atherosclerosis.	
Compared	to	normal	arteries,	Sirt6	levels	are	decreased	in	atherosclerotic	aortae	of	
Apoe	 KO	 mice	 and	 in	 human	 plaques	 [73].	 These	 findings	 suggest	 an	



























For	 this	 purpose,	 we	 analysed	 the	 effects	 of	 heterozygous	 deletion	 of	 Sirt6	 on	








To	 this	 end,	 we	 analyzed	 the	 effects	 of	 bone	 marrow	 transplantation	 of	 Sirt6-
deficient	bone	marrow	cells	 into	Apoe-/-	recipient	mice	on	atherogenesis,	 foam	cell	
formation	and	scavenger	receptor	expression.	









male	Apoe-/-	 and	Apoe-/-	 Sirt6+/-	 mice	 were	 fed	 a	 high-cholesterol	 diet	 (HCD)	 with	
1.25%	cholesterol	 for	12	weeks	 (Figure	6).	At	 the	end	of	12	weeks,	 the	mice	were	
harvested	to	assess	for	total	en	face	thoracoabdominal	plaque	content	by	oil	red	O	
staining.	Plasma	total	cholesterol,	triglycerides	and	various	lipoprotein	sub	fractions	














irradiated	 to	destroy	 the	 resident	BM	cells	and	 then	 injected	with	donor	BM	cells.	
The	 recipient	 Apoe-/-	 mice	 were	 then	 allowed	 6	 weeks	 for	 complete	 BM	
reconstitution	after	which	they	were	fed	a	high-cholesterol	diet	(HCD)	for	12	weeks	
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Background:	 Macrophage	 Scavenger	 Receptor	 1	 (Msr1)	 mediates	 the	 uptake	 of	




Methods	 and	 Results:	 Heterozygous	 constitutive	 Sirt6	 deletion	 did	 not	 affect	
atherosclerosis	 in	 Apoe-/-	 mice	 fed	 a	 high-cholesterol	 diet	 (HCD)	 for	 12	 weeks.	
However,	 bone	 marrow	 (BM)-specific	 Sirt6	 deletion	 increased	 aortic	 plaque	
formation	 in	Apoe-/-	mice	 on	 a	 HCD.	 Aortic	 root	 sections	 from	 Sirt6-deficient	 BM-
transplanted	 mice	 revealed	 an	 increase	 in	 lipid	 content,	 macrophage	 numbers,	
Vcam1	 expression	 and	 macrophage	 Msr1	 levels.	 Plasma	 lipids	 and	 circulating	
cytokines	 were	 similar	 between	 the	 groups.	 In	 RAW	 264.7	 macrophages,	 Sirt6	
knockdown	 enhanced	 Dil-labelled	 oxLDL	 uptake,	 whereas	 Sirt6	 overexpression	
reduced	 it;	 silencing	 of	 Sirt6	 increased	 mRNA	 and	 protein	 expression	 of	 Msr1,	
whereas	 the	 expression	 of	 other	 macrophage	 lipoprotein	 uptake	 and	 efflux	
receptors	remained	unchanged.	Double	knockdown	of	Sirt6	and	Msr1	 in	RAW	cells	
abolished	 the	 increase	 in	 oxLDL	 uptake.	 BM-derived	 macrophages	 revealed	
increased	Msr1	 protein	 expression	 in	Apoe-/-	 Sirt6-/-	 compared	with	Apoe-/-	 Sirt6+/+	
donors.	 Flow	 cytometric	 analysis	 of	 macrophages	 from	 aortic	 plaques	 of	 Sirt6-
deficient	 BM-transplanted	mice	 showed	 increased	Msr1	 expression;	 similar	 results	













low-density	 lipoproteins	 (LDL)	 are	 a	 key	 driver	 of	 atherosclerosis.	 Excess	 LDL	 is	
retained	 in	 the	 subendothelial	 space.	 If	 exposed	 to	 oxidative	 stress,	 they	 may	
transform	 into	 oxidised	 LDL	 (oxLDL).	 This	 modified	 LDL	 (mLDL)	 is	 taken	 up	 by	
scavenger	receptors	such	as	scavenger	receptor	A,	synonymous	in	mice	with	mouse	
scavenger	receptor	1	 (Msr1),	CD36	and	oxidized	 low-density	 lipoprotein	receptor	1	
(Lox1)	leading	to	macrophage	foam	cell	formation.	Atherogenesis	occurs	when	these	
excess	circulating	LDL-cholesterol	 (LDL-c)	and	 its	modified	forms	accumulate	within	
the	 vascular	 intima	 triggering	 endothelial	 dysfunction,	 local	 inflammation,	 plaque	
formation	and	vascular	remodelling	leading	to	the	narrowing	of	coronary	or	cerebral	





H3	 lysine	 56	 (H3K56)	 [75].	 By	means	 of	 this	 histone	 deacetylation,	 Sirt6	maintains	
chromatin	 conformation	 and	 regulates	 telomere	 stability,	 DNA	 repair	 and	 gene	





chronic	 liver	 inflammation	 and	 fibrosis,	 in	 part	 due	 to	 c-Jun	 activation	 [77,	 78].	
Similarly,	 bone	 marrow-derived	 macrophages	 isolated	 from	 Sirt6-null	 mice	 show	
increased	 Mcp-1,	 Il-6,	 and	 TNFα	 expression	 levels	 and	 are	 hypersensitive	 to	 LPS	
stimulation	[77].	
Sirt6	has	been	shown	to	have	an	important	role	 in	metabolic	diseases:	Sirt6	










Sirt6	 loss-of-function	 experiments	 in	 cultured	 macrophages	 using	 a	 knockdown	










+/-	 mice	 (provided	 by	 Johan	 Auwerx,	 EPFL)	 and	 Apoe-/-	 (Charles	 River,	
Italy)	were	bred	 in-house	under	pathogen–free	conditions	housed	with	a	12	hours	
light	–	dark	cycle	and	fed	a	high-cholesterol	diet	(HCD)	containing	1.25%	cholesterol	
(D12108;	 Research	Diets,	New	Brunswick,	USA)	 for	 12	weeks.	 All	 experiments	 and	
animal	 care	 procedures	 were	 approved	 by	 the	 local	 and	 cantonal	 veterinary	
authorities	and	carried	out	in	accordance	with	the	local	institutional	guidelines.		
For	 the	 generation	 of	 bone	marrow	 chimeras,	 6	week-old	 female	Apoe-/-	 recipient	
mice	were	sub-lethally	irradiated	with	two	doses	of	550	rads	each.	3	week-old	donor	
mice	were	killed	by	CO2	inhalation	and	bones	(hind	limbs	and	hips)	were	flushed	with	
sterile	 PBS	 to	 obtain	 bone	 marrow	 (BM)	 cells.	 Donor	 BM	 cells	 were	 injected	
intravenously	(2	×	107	total	cells	per	mouse),	and	to	prevent	bacterial	infection	0.2%	
(vol/vol)	 Borgal	 (trimethoprim,	 sulfadoxin)	 was	 added	 to	 the	 drinking	 water	 for	 1	
week	and	mice	were	allowed	to	recover	for	6	weeks	and	then	were	exposed	to	12-
weeks	 of	 HCD.	 To	 confirm	 bone	 marrow	 chimerism,	 a	 control	 experiment	 with	









Knockdown	 experiments	 were	 performed	 using	 lipofectamine	 RNAiMAX	 (Life	









Aortic	 root	 tissues	 were	 embedded	 in	 OCT	 and	 sectioned	 (5μm	 thick).	 For	






Inflammatory	 cytokines	 (Mcp-1	 and	 Il-6)	 were	 measured	 using	 ELISA	 kits	 from	
Thermo	Scientific	according	to	the	manufacturer’s	protocol.	
Cholesterol	profiles	and	lipoprotein	fractions	
Cholesterol	 and	 triglyceride	 plasma	 concentrations	 were	 measured	 using	
colorimetric	and	enzymatic	methods	with	ready	to	use	kits	 (BioMérieux).	To	assess	





and	 analysed	 with	 FlowJo	 software	 (Tree	 Star).	 Cells	 isolated	 from	 the	 blood	 and	










cDNA	 using	 MML-V	 reverse	 transcriptase	 or	 Superscript	 II	 RT,	 followed	 by	 PCR	














All	 data	 are	 presented	 as	 mean	 ±	 SEM.	 Data	 distribution	 was	 assessed	 using	 the	
Kolmogorov	 –	 Smirnov	 test.	 Normally	 distributed	 data	 were	 compared	 using	 an	
unpaired	 two-tailed	Student’s	 t-test;	 for	non-parametric	data	 the	Mann	–	Whitney	
test	was	used.	Three	or	more	groups	were	 compared	using	a	Kruskal	–	Wallis	 test	
followed	 by	 a	 Dunn’s	 post-hoc	 comparison	 (non-parametric	 data).	 At	 least	 three	









Since	 constitutive	 homozygous	 Sirt6	 deletion	 confers	 embryonic	 and	 early	 life	
lethality	[76],	we	assessed	the	effects	of	constitutive	heterozygous	Sirt6	deletion	on	
atherosclerosis.	 Thus,	Apoe-/-Sirt6+/-	and	Apoe-/-Sirt6+/+	mice	were	 fed	a	HCD	 for	12	
weeks.	Comparisons	of	thoraco-abdominal	aortae	en	face	and	serial	aortic	root	cross	





Sirt6	 protein	 levels	 than	 Apoe-/-Sirt6+/+;	 however,	 there	 was	 no	 change	 in	 the	
acetylation	 status	 of	 the	 Sirt6	 targets-H3K9	 or	 H3K56	 (Figure	 1E).	 Plasma	 lipid	
analyses	 showed	 that	 cholesterol	 and	 triglyceride	 levels	 including	 lipoprotein	







from	 Apoe-/-Sirt6+/+	 Apoe-/-	 or	 Apoe-/-Sirt6-/-	 donor	 mice	 were	 transplanted	 into	
irradiated	 Apoe-/-	 recipient	 mice.	 Following	 6	 weeks	 of	 recovery	 with	 BM	
reconstitution,	mice	were	 fed	 a	HCD	 for	 12	weeks.	En	 face	 plaque	 staining	 of	 the	
thoraco-abdominal	aortae	revealed	a	significant	increase	in	atherosclerosis	in	Apoe-/-
Sirt6
-/-	 BM-recipient	 mice	 compared	 with	 Apoe-/-Sirt6+/+	 Apoe-/-	 BM-recipient	 mice	
(Figure	2A).	Blood	haematological	analyses	showed	that	the	count	of	the	cell	types	is	
similar	between	both	 the	groups	after	BM-transplantation	 (Supplemental	Table	1).	
Oil-red	 O	 staining	 of	 serial	 aortic	 root	 cross	 sections	 showed	 an	 increase	 in	 lipid	




root	 cross-sections	 from	 the	 Apoe-/-Sirt6-/-	 BM-recipient	 mice	 showed	 increased	




(Figure	 2E).	 Plasma	 lipid	 analyses	 showed	 that	 cholesterol	 and	 its	 lipoprotein	
subfractions	were	similar	between	the	two	groups	(Figure	2F-G)	and	additionally,	no	








uptake,	 in	 vitro	 in	 RAW	264.7	 cell	 accumulation	of	 oxLDL	was	measured.	 First,	we	
confirmed	 that	 the	 expression	 levels	 of	 Sirt6	 are	 reduced	 upon	 Sirt6	 knockdown	
(Figure	 3A).	 Sirt6	 silencing	 increased	 oxLDL	 accumulation	 in	 vitro	 (Figure	 3B,	 C).	
Conversely,	Sirt6	overexpression	(Figure	3D)	reduced	oxLDL	accumulation	(Figure	3E,	
F).	 These	 findings	 indicate	 that	macrophages	with	 the	deficiency	of	 Sirt6	are	more	
prone	to	foam	cell	formation	upon	exposure	to	mLDL.	
Sirt6	limits	macrophage	oxLDL	accumulation	by	suppressing	Msr1	expression	
To	 address	 the	 mechanism	 underlying	 the	 increase	 in	 oxLDL	 uptake	 upon	 Sirt6	
deficiency,	we	assessed	the	effects	of	 silencing	of	Sirt6	on	 the	expression	of	genes	
involved	 in	 cellular	 cholesterol	 accumulation.	 Knockdown	 of	 Sirt6	 increased	
scavenger	 receptor	 Msr1	 mRNA	 and	 protein	 expression,	 but	 did	 not	 alter	 mRNA	
expression	 of	 other	 scavenger	 receptors	 such	 as	 Cd36	 or	 Lox1.	 (Figure	 4A,	 B).	
Furthermore,	mRNA	 levels	 of	 the	 cholesterol	 efflux	 transporters	Abca1	 and	Abcg1	
were	 not	 altered	 (Figure	 4A).	 Conversely,	 adenovirus-mediated	 overexpression	 of	
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and	 Sirt6.	Msr1	 knockdown	 abolished	 the	 increase	 in	 Dil-oxLDL	 uptake	 upon	 Sirt6	
knockdown	 (Figure	 4D,	 E),	 confirming	 that	 Msr1	 is	 a	 necessary	 mediator	 for	
increased	oxLDL	accumulation	in	Sirt6-deficient	macrophages.	In	parallel,	Msr1	levels	




	 BM	 transplantation	 increases	Msr1	 expression	 in	 BM	 cells	 and	 in	 mouse	
aortic	plaque	macrophages		
To	assess	 the	 in	 vivo	 relevance	of	Msr1	expression	 in	our	 Sirt6-BM	atherosclerosis	
phenotype,	we	analysed	Msr1	expression	in	BM-recipient	mice	to	ascertain	whether	




mice	 (Figure	5A,	B).	 Immunofluorescence	analyses	of	 aortic	 root	 sections	 revealed	
increased	 Msr1	 expression	 in	 macrophages	 of	 Apoe-/-Sirt6-/-	 BM-recipient	 mice	
compared	with	Apoe-/-Sirt6+/+	BM-recipient	mice	(Figure	5C).	
Furthermore,	 we	 assessed	 Msr1	 levels	 in	 aortic	 arch	 plaque	 macrophages.	 Flow	
cytometric	 analyses	 showed	an	 increased	expression	of	Msr1	 in	 the	 Ly6C+F4/80high	
aortic	macrophages	 of	Apoe-/-Sirt6-/-	 BM-recipient	mice	 relative	 to	 the	Apoe-/-	 BM-
recipient	mice	(Figure	5D).	Interestingly,	corresponding	analyses	in	blood	monocytes	


























































































































































Figure	 2.	 Hematopoietic	 homozygous	 Sirt6	 deficiency	 increases	 atherosclerosis.	 Bone	




thoraco-abdominal	 aortae	 stained	 with	 Oil	 Red	 O	 (ORO,	 left	 panel)	 and	 corresponding	
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quantification	 of	 Dil-oxLDL	 uptake	 upon	 scramble	 or	 Sirt6	 knockdown.	C,	Western	 blot	 of	
Sirt6	protein	 levels	upon	the	overexpression	of	Sirt6	using	V5-tagged	Sirt6	adenovirus	 (Ad-









































































Figure	 4.	 Sirt6	 regulates	 macrophage	 oxLDL	 accumulation	 via	 Msr1.	 A,	 Relative	 mRNA	
expression	levels	of	genes	involved	in	modified	low-density	lipoprotein	uptake	and	efflux.	B,	
Knockdown	 of	 Sirt6	 increases	 Msr1	 protein	 compared	 to	 control	 levels	 in	 RAW	 264.7	
macrophages.	 C,	 Sirt6	 overexpression	 decreases	Msr1	 protein	 levels	 compared	 to	 control	













































































































































































Figure	 5.	 Hematopoietic	 Sirt6	 deficiency	 increases	 Msr1	 expression	 in	 BM	 and	 aortic	
plaque	macrophages.	A,	Msr1	mRNA	and	B,	Msr1	protein	expression	is	increased	in	the	BM	
cells	 of	 Apoe-/-	 Sirt6+/+	 and	 Apoe-/-Sirt6-/-BM	 transplanted	 mice.	 C,	 Immunofluorescence	 of	
Msr1	and	CD68	showing	more	macrophage-associated	Msr1	expression	in	cross	sections	of	
the	aortic	root	of	Apoe-/-	Sirt6-/-BM	transplanted	mice	compared	with	the	Apoe-/-	Sirt6+/+	BM	
transplanted	mice	 (bar	 =	 20	mm,	 insert:	 bar	 =	 30	mm).	 	D-E,	 Msr1	 expression	 levels	 are	
higher	 in	 Ly6C+F4/80high	 macrophage	 population	 in	 Apoe-/-	 Sirt6-/-	 BM	 transplanted	 mice	
compared	with	the	Apoe-/-	Sirt6+/+	BM	transplanted	mice	(n=7).	F-G,	Msr1	expression	 levels	
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Supplemental	 Figure	 1.	 A,	 Weight-course	 of	 Apoe-/-	 Sirt6+/+	 and	 Apoe-/-Sirt6-/-BM	
transplanted	 mice	 during	 12-weeks	 on	 HCD.	 B,	 Sirt6	 expression	 in	 aortic	 root	 sections	
showing	the	accumulated	macrophages	in	Apoe-/-Sirt6-/-BM	transplanted	mice	expresses	no	
Sirt6.	C,	Control	chimerism	experiment	using	CD45.1	donor	cells	 injected	 in	CD45.2	Apoe-/-	
mice	 showing	 complete	 reconstitution	 of	 mice	 with	 donor	 BM.	 D,	 Protein	 expression	 of	
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Apoe-/-  Sirt6+/+ BMT 6.94 6.94 12.92 38.54 43.8 1070.8 10.38 
Apoe-/- Sirt6-/- BMT 6.18 6.18 12 33.66 44.2 969.6 10.6 








As	 the	 nuclear	 Sirt6	 exhibits	 a	 profound	 phenotype	with	 a	 progeria-like	 syndrome	
with	 severe	 hypoglycemia	 and	 early	 lethality	 [52],	 the	 effects	 of	 constitutive	
homozygous	 Sirt6	 deletion	 cannot	 be	 studied	 in	 atherosclerosis.	 Thus,	we	 studied	
the	effects	of	heterozygous	deletion	of	Sirt6	in	atherosclerotic	Apoe-/-	mice.			
Patients	with	diabetes	show	lower	Sirt6	expression	in	carotid	atherosclerotic	
plaques	 than	 non-diabetic	 patients,	 suggesting	 that	 the	 risk	 factor	 diabetes	 is	
associated	with	 low	Sirt6	expression	 in	human	carotid	 atherosclerosis	 [81].	Recent	
studies	 have	 shown	 that	 Sirt6	 heterozygous	 mice	 exhibit	 impaired	 endothelial	
dysfunction	and	increased	oxidative	stress	[54].	As	endothelial	dysfunction	precedes	
atherosclerosis,	these	reports	imply	that	heterozygous	Sirt6	deletion	would	increase	
atherosclerosis.	 However,	 in	 our	 hands,	 using	 heterozygous	 constitutive	 Sirt6	
deletion	was	not	sufficient	to	change	atherosclerosis	in	Apoe-/-	mice.	We	show	that	
the	 heterozygous	 deletion	 of	 Sirt6	 causes	 a	 40%	 reduction	 of	 Sirt6	 expression	 to	
control	in	the	liver,	however	it	is	possible	that	this	40%	reduction	is	not	detrimental	
enough	to	elicit	a	phenotype.		As	complete	loss	of	Sirt6	in	mice	is	lethal	after	4	weeks	
of	 age	 with	 severe	 metabolic	 defects,	 it	 is	 possible	 that	 the	 available	 Sirt6	 in	
heterozygous	Sirt6	knockout	mice	 is	already	adequate	 for	 the	body	 to	prevent	 the	
adverse	effects	of	 the	complete	absence	of	Sirt6.	Another	possible	explanation	 for	





83].	This	discrepancy	might	be	a	 result	of	differences	 in	experimental	protocols.	 In	
one	of	 the	publications,	 the	mice	were	 fed	 a	HFD	 instead	of	HCD	 for	of	 16	weeks	
starting	at	4	weeks	of	age	[83]	instead	of	the	12-weeks	on	HCD	we	have	used.	While	
another	 paper	 fed	 the	 heterozygous	 Sirt6	 knockout	mice	 a	HFD	 for	 duration	 of	 8-
weeks	and	then	assessed	for	atherosclerosis	[73].	
	
















mRNA	 and	 protein	 expression	 in	 Apoe-/-	 mice.	 Previous	 studies	 have	 shown	 that	
genetic	 Msr1	 loss-of-function	 in	 Apoe-/-	 mice	 results	 in	 a	 60%	 decrease	 in	
atherosclerotic	lesions,	highlighting	the	significance	of	Msr1	for	the	development	of	
atherosclerosis	in	mice	[85-88].	The	increase	in	Msr1	expression	upon	Sirt6	deletion	
in	 both	 BM-derived	 macrophages	 (BMDM)	 from	 the	 donor	 BM	 cells	 before	 BM-
transplantation	and	 in	BM-derived	cells	after	BM-transplantation	after	12	weeks	of	
HCD	 suggests	 that	 Msr1	 plays	 an	 important	 role	 for	 plaque	 formation	 in	 our	
atherosclerosis	model.	
To	improve	mechanistic	insight,	we	extended	our	in	vivo	Sirt6	loss-of-function	
findings	 to	an	 in	vitro	model:	Sirt6	knockdown	and	overexpression	studies	 in	RAW	
264.7	 macrophages	 specified	 that	 Sirt6	 knockdown	 indeed	 increased	Msr1	 mRNA	
and	 protein	 expression;	 the	 fact	 that	 Sirt6	 deletion	 increased	 foam	 cell	 formation	
and	oxLDL	uptake	gave	these	molecular	changes	a	functional	relevance	and	provided	
an	explanation	for	the	in	vivo	phenotype.	Finally,	the	absence	of	oxLDL	uptake	upon	





Recent	 studies	 have	 suggested	 a	 rapid	 turnover	 of	 macrophages	 in	
atherosclerotic	lesions.	This	increase	in	proliferation	has	been	suggested	to	be	due	to	
an	increase	in	Msr1	expression	leading	to	an	increase	in	atherosclerosis	progression	
[89].	 We	 identified	 CD45+CD11b+	 Ly6C+	 F4/80	 high	macrophages	 by	 flow	 cytometry	
from	plaques	of	aortic	arches	of	Apoe-/-Sirt6-/-	and	Apoe-/-Sirt6+/+	BM	recipient	mice	
fed	a	HCD.	We	 found	a	 significant	 increase	 in	Msr1	expression	 in	 the	macrophage	

















atherosclerosis	 and	 contributes	 to	 an	 increased	 risk	 of	 coronary	 events.	 Here,	 we	
demonstrated	that	the	deficiency	of	Sirt6	in	macrophages	is	proatherosclerotic	and	
upregulates	Msr1	expression	both	 in	vivo	and	 in	vitro.	In	RAW	macrophages	Sirt6	is	
able	 to	 downregulate	 Msr1	 expression	 and	 prevent	 the	 increased	 oxLDL	
accumulation.	 As	 it	 has	 been	 reported	 that	 Sirt6	 overexpression	 prevents	 against	
HFD	 in	mice,	 it	 is	 possible	 that	 this	 protection	 against	 obesity	might	 be	 linked	 to	
scavenger	 receptor	 expression	 (33).	 Other	 reports	 have	 mentioned	 that	 Sirt6	 has	
anti-inflammatory	benefits	via	its	effects	on	NF-κB	mediated	signalling.	Although	the	
BM-specific	 deletion	 of	 Sirt6	 does	 not	 have	 a	 potent	 effect	 of	 whole	 body	
inflammation,	it	is	likely	that	the	local	lesion	site	inflammation	is	affected.	
Our	findings	with	regard	to	Sirt6	affecting	Msr1	and	modified	LDL	uptake	bolster	the	
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The	 current	 thesis	 focuses	 on	 investigating	 the	 effects	 of	 Sirt6	 deletion	 on	
atherosclerosis.	We	have	shown	that	heterozygous	deletion	of	Sirt6	does	not	affect	
atherosclerosis	 in	Apoe-/-	mice	compared	to	control	mice.	However,	atherosclerosis	
was	 increased	 in	 Apoe-/-	 mice	 transplanted	 with	 Sirt6-deficient	 bone	 marrow	
compared	to	Apoe-/-	mice	transplanted	with	wild-type	bone	marrow.	These	findings	
show	that	Sirt6	indeed	plays	a	pro-atherosclerotic	role	in	macrophages.		
Although	 others	 and	 we	 have	 demonstrated	 that	 Sirt6	 deletion	 increases	
atherosclerosis,	 the	 role	 of	 Sirt6	 overexpression	 on	 atherosclerosis	 remains	 to	 be	
investigated	 [73,	 83].	 Constitutive	 Sirt6	 overexpressing	mice	 exhibit	 reduced	 LDL-c	
when	 placed	 on	 a	 high-fat	 diet	 [62]	 and	 Sirt6	 also	 reduces	 LDL-c	 by	 means	 of	
regulating	 PCSK9	 [91].	 This	 suggests	 that	 Sirt6	 overexpression	 may	 be	 athero-
protective	through	an	increase	in	hepatic	LDL-R	and	a	decrease	in	plasma	PCSK9	and	
LDL-c	 levels.	 Sirt6	 is	 also	 known	 to	 improve	 other	 risk	 factors	 of	 the	 metabolic	
syndrome	 such	 as	 insulin	 resistance,	 triglyceride	 synthesis	 and	 hepatic	 steatosis.	
Thus,	the	role	of	Sirt6	overexpression	needs	to	be	investigated	in	the	context	of	both	
an	Apoe-/-	model	 and	 an	 Ldlr-/-	model	 to	 distinguish	 between	 the	 atheroprotective	
effects	 of	 non-HDL	 lipoproteins	 and	 glucose	 metabolism.	 We	 anticipate	 that	
atherosclerotic	effects	of	Sirt6	overexpression	in	Apoe-/-	mice	are	different	from	Ldlr-
/-	mice.		






-/-	 mice.	 However,	 since	 both	 studies	 show	 a	 change	 in	 Sirt6	 activity,	 the	
discrepancy	 in	 our	 findings	may	 lie	 in	 the	 difference	 in	 design	 of	 our	 Sirt6-/-	 mice	
experiments.	Of	note,	similar	to	publications	of	Sirt1	deletion	and	the	mechanism	of	
atherosclerosis	 in	Apoe-/-	mice,	 studies	 of	 Sirt6	 and	 atherosclerosis	 in	Apoe-/-	mice	
demonstrate	different	protagonist	cells	such	as	NK	cells	in	Sirt6	heterozygous	mouse	
and	 vascular	 cells	 in	 shRNA-mediated	 knockdown	of	 Sirt6,	while	we	 show	Msr1	 in	
macrophages.	 These	 findings	demonstrate	novel	 roles	of	 Sirt6	 in	NK	 cells,	 vascular	
endothelial	cells	and	macrophages.	Thus,	Sirt6	might	play	a	diverse	role	in	different	









highlights	 a	 novel	 aspect	 of	 Sirt6	 being	 involved	 in	macrophage	 lipid	metabolism.	
Macrophages	 are	 important	 contributors	 to	 atherogenesis.	 Since	 we	 have	
demonstrated	 that	 Sirt6	 regulates	 an	 important	 macrophage	 lipid	 influx	 moiety	 –	
Msr1,	 it	 would	 be	 interesting	 to	 further	 assess	 whether	 Sirt6	 also	 plays	 a	 role	 in	
other	aspects	of	macrophage	lipid	metabolism	and	plaque	progression.	






for	many	 genes	 involved	 efferocytosis.	 Sirt6	 overexpression	 downregulates	 PPARγ	
gene	 expression	 [62].	 Similarly,	 miR-34a	 is	 known	 to	 negatively	 regulate	
efferocytosis	 [92].	 Sirt6	 is	 a	 miR-34a	 target	 downregulated	 during	 differentiation	




in	 the	 intima	 and	 trigger	 inflammatory	 responses.	 This	 causes	 increased	 ER	 (endoplasmic	
reticulum)	stress	that	in	turn	leads	to	macrophage	apoptosis	and	defective	efferocytosis.	The	
apoptotic	 cells	 become	necrotic	 cells,	 contributing	 to	 necrotic	 core	 formation.	Necrosis	 of	








The	 leukocyte	 adhesion	 cascade	 comprises	 steps	 that	 facilitate	 the	 entry	 of	
monocytes	 into	 the	 arterial	 intima,	 including	 the	 adhesion	 of	 monocytes	 to	 the	
endothelium	 (depends	 on	 the	 upregulation	 on	 activated	 endothelial	 cells	 of	
molecules),	rolling	which	 is	mediated	by	selectins,	activation	(which	 is	mediated	by	
chemokines)	 and	 arrest	 (which	 is	 mediated	 by	 integrins)	 [95].	 Sirt6	 reduced	 the	
expression	of	 inflammatory	 cytokines	 such	as	P-selection,	VCAM1	and	 ICAM1.	 It	 is	
possible	that	Sirt6	provides	athero-protection	by	downregulating	these	cytokines	at	
the	different	stages	plaque	formation.		
For	 patients	 with	 coronary	 or	 cerebral	 atherosclerosis,	 understanding	
atherogenesis	 is	 important	 in	 terms	of	preventing	or	decreasing	plaque	 formation.	
However,	plaque	regression	would	be	the	ultimate	goal.	My	studies	have	proven	the	
Sirt6	is	important	for	experimental	atherogenesis.	It	will	also	be	interesting	to	study	
the	 role	 of	 Sirt6	 in	 aspects	 of	 plaque	 regression.	 Atherosclerosis	 regression	 is	
typically	 associated	 with	 a	 decrease	 in	 atherosclerotic	 plaque	 size	 with	 a	 marked	
reduction	 in	 lipid	 levels,	 immune	 cells	 and	 inflammatory	 gene	 expression.	
Transcriptomic	 profiling	 of	 macrophages	 isolated	 from	 an	 aortic	 transplantation	
mouse	model	of	progressing	and	regressing	plaques	 identified	>700	genes	that	are	







drug	 or	 treatment	 is	 equally	 important.	 The	 best	 approach	would	 be	 to	 abrogate	
early	plaque	development,	when	efferocytosis	is	most	efficient,	and	the	apoptosis	of	
accumulating	plaque	cells.	To	retard	plaque	progression,	agents	such	as	Il-10	or	LXR	




be	 interesting	 to	 check	 whether	 Sirt6	 also	 regulates	 these	 and	 if	 the	 plaque	
regressive	effects	are	actually	prompted	by	a	shift	in	Sirtuins	activity	locally.	Another	
possible	way	to	determine	if	Sirt6	is	indeed	involved	in	plaque	regression	is	by	doing	
a	 ChIP-sequencing	 of	macrophages	 isolated	 from	 an	 aortic	 transplantation	mouse	
model	of	progressing	and	 regressing	plaques	and	assessing	 for	common	targets	by	
transcriptomic	profiling.	
While	 the	 concept	 of	 plaque	 regression	 in	 patients	 appears	 appealing,	
translation	 of	 experimental	 findings	 to	 patients	 with	 atherosclerosis	 appears	









[100]	and	 the	production	of	neurotoxins	upon	central	nervous	 system	 (CNS)	 injury	
[101].	 In	 line	with	this,	Sirt6-/-	mice	show	an	 increase	 in	DNA	damage,	suggesting	a	
physiological	role	of	Sirt6	in	maintaining	integrity	of	neural	cells	[102].		
Msr1	 has	 also	 been	 shown	 to	 play	 a	 role	 in	 retinitis	 pigmentosa	 (retinal	




risk	 to	 prostate	 cancer	 [105],	 while	 polymorphisms	 in	 Msr1	 are	 also	 linked	 to	
increased	 incidence	 of	 prostate	 cancer	 as	 seen	 from	 epidemiological	 studies	 [106,	
107].	While	overexpression	of	Sirt6	 increases	cell	viability	 in	prostate	cancer	 [108].		
However,	 studies	have	not	yet	addressed	 the	 role	of	Sirt6	and	Msr1	 in	CNS	 injury,	






activity.	 Since	 Sirt1	 was	 the	 first	 sirtuin	 to	 be	 investigated,	 most	 of	 the	 available	
sirtuin	 activating	 compounds	 (STACs)	 targeted	 Sirt1.	 Resveratrol	 –	 a	 naturally	
occurring	 compound	 was	 the	 first	 STAC	 that	 was	 identified	 by	 screening	 for	
	
	 68	
deacetylation	of	 synthetic	 peptidyl	 substrates	 labeled	with	 a	 chemical	 fluorophore	
group	[109,	110]	which	was	later	shown	to	be	non-specific	screening	method	[109].	
The	 discovery	 of	 natural	 STACs	 such	 as	 resveratrol	 was	 a	 proof-of-concept	
that	 prompted	 screening	 for	 synthetic	 Sirt1	 activators	 that	 were	 more	 potent,	
soluble	 and	 bioavailable	 [109].	 STACs	 such	 as	 SRT1720	 and	 SRT2104	 have	 been	
tested	in	human	clinical	trials	for	different	indications	such	as	psoriasis,	skin	cancer,	
lymphoma	among	others	[110,	111]	–	including	cardiovascular	diseases	(see	below).		
The	experimental	 beneficial	 effects	of	 Sirt1	 activation	prompted	 the	 search	
for	Sirt6	activators.	Unfortunately,	there	are	no	commercially	STACs	specific	for	Sirt6	
available	however	recently	a	patent	application	have	been	filed	for	a	Sirt6	activator	
where	 the	 compound	 increases	 the	deacetylation	activity	of	 Sirt6.	 	 The	 compound	





of	 Sirt6	 have	 been	 identified.	 The	 nuclear	 lamins,	 in	 conjunction	 with	 their	
interacting	 partners,	 form	 a	 complex	 network	 of	 proteins	 that	 are	 critical	 for	 the	
mechanical	support	of	the	nuclear	envelope,	and	maintenance	of	proper	chromatin	
organization	and	transcriptional	regulation	[112].		It	was	recently	shown	that	lamin	A	









The	 available	 STACs	 have	 been	 tested	 in	 numerous	 animal	models	 and	 have	 been	
tested	 in	 clinical	 trials	 for	 their	beneficial	 effects.	 Studies	have	 shown	 that	 in	diet-




Sirt6	 overexpression	 reduces	 LDL-c	 levels,	 it	 is	 possible	 that	 Sirt6	 activation	would	
also	 protect	 against	 atherosclerosis.	 Alternatively,	 since	 Sirt6	 knockout	 mice	 are	
hypoglycemic	 and	 overexpression	 improves	 insulin	 sensitivity,	 Sirt6	 activation	may	
also	be	beneficial	 in	treating	metabolic	syndrome	–	a	risk	 factor	of	atherosclerosis.	












metabolism	 and	 oxidative	 stress,	 increasing	 availability	 of	 NAD+	 [117].	 Hence,	 a	
natural	way	to	increase	the	activity	of	sirtuins	is	by	caloric	restriction.		
The	modulation	 of	 intracellular	 NAD+	 levels	 is	 another	method	 to	 increase	
sirtuin	activity	and	mimic	its	beneficial	effects.	This	can	be	achieved	by	two	different	
strategies	–	 increasing	NAD+	 biosynthesis	or	decreasing	NAD+	 consumption.	During	
the	 biosynthesis	 of	 NAD+	 within	 cells,	 the	 enzyme	 nicotinamide	
phosphoribosyltransferase	 (NAMPT)	 catalyses	 the	 rate	 limiting	 step	 of	 converting	
nicotinamide	 to	 nicotinamide	 mononucleotide	 (NMN)	 and	 pyrophosphate	 [118].	
NMN	 is	 then	 converted	 to	 NAD+	 by	 the	 isoenzyme	 nicotinamide	 mononucleotide	
adenylyltransferase	(NMNAT).	
Currently,	 few	 studies	 have	 addressed	 the	 modulation	 of	 NAD+	 levels	 by	
supplementation	 of	 tryptophan	 and	 nicotinic	 acid	 (NA).	 Tryptophan	 is	 the	 main	

















My	 PhD	 project	 demonstrates	 that	 specific	 loss	 of	 Sirt6	 in	 BM-derived	 cells	 in	
proatherosclerotic	 by	 upregulating	 Msr1	 expression,	 without	 affecting	 systemic	
inflammation.	It	emphasizes	the	importance	of	BM-derived	cells	in	atherogenesis.	It	
also	 spotlights	 the	 contribution	 of	 the	 local	 aortic	 mmLDL	 uptake	 by	 scavenger	
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